The Gallay Laboratory

Selected References

de Witte, L., Bobardt, M.D., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and Gallay, P. A. 2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. 104: 19464-9.

Bobardt, M., Cheng, G., de Witte, L., Selvarajah, S., Chatterji, U., Beer, B., Geijtenbeek, T. B. H., Chisari, F. V., and Gallay, P. A. 2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 105: 5525-30.

Chatterji, U., Bobardt, M., Selvarajah, S., Yang,F., Tang, H. Sakamoto, N Vuagniaux, G., Parkinson, T., and Gallay, P. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284:16998-7005.

Hopkins, S., DiMassimo, B, Rusnak, P., Heuman, D., Lalezari, J., Sluder, A.,Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., and Gallay, P.A. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 57:47-54.

Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C.S., Penin, F., and Gallay, P.A. 2012. Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities. Antimicrob. Agents Chemother. 56:3336-43.

Lim, P.J., Chatterji, U., Cordek, D., Sharma, S.D., Garcia-Rivera, J.A., Cameron, C.E., Lin, K., Targett-Adams, P., and Gallay, P.A. 2014. Correlation between NS5A dimerization and hepatitis C virus replication. J. Biol. Chem. 287:308611-73.

Bobardt, M., Hopkins, S., Baugh, J., Chatterji, U., Hernandez, F., Hiscott, J., Sluder, A., Lin, K., and Gallay, P.A. 2013. HCV NS5A and IRF9 compete For CypA binding. J. Hepatol. 58:16-23.

Gallay, P.A., Ptak, R.G., Bobardt, M.D, Dumont, J.-M., Vuagniaux, G. and Rosenwirth, B. 2013. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses 5:981-97.

Gawlik, K., Baugh, J., Chatterji, U., Lim, P.J., Bobardt, M.D., and Gallay, P.A. 2014. HCV Core residues critical for infectivity are involved in core-NS5A interactions. PLoS One. 9(2):e88866.

Chatterji, U., Garcia-Rivera, J.A., Baugh, J., Gawlik, K., Wong, K.A., Zhong, W., Brass, C.A., Naoumov, N.V. and Gallay, P.A. 2014. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother. 58(6):3327-3334.